The interindividual differences in the 3‐demthylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors

Factor Analysis and AIC

Akaike, H. (1987) · Psychometrika · doi:10.1007/bf02294359 · Cited by 5,264

POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN

Mahgoub, A., Dring, L. G., Idle, J. R., Lancaster, R., & Smith, R. L. (1977) · The Lancet · doi:10.1016/s0140-6736(77)91430-1 · Cited by 1,183

Functional significance of a C–>A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine

Sachse, C., Brockmöller, J., Bauer, S., & Roots, I. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00898.x · Cited by 751

Potential Role of Pharmacogenomics in Reducing Adverse Drug Reactions

Phillips, K. A., Veenstra, D. L., Oren, E., Lee, J. K., & Sadée, W. (2001) · JAMA · doi:10.1001/jama.286.18.2270 · Cited by 705

A twin-pronged attack on complex traits

Martin, N. G., Boomsma, D. I., & Machin, G. A. (1997) · Nature Genetics · doi:10.1038/ng1297-387 · Cited by 654

Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines.

Butler, M. A., Iwasaki, M., Guengerich, F. P., & Kadlubar, F. F. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.20.7696 · Cited by 638

Defective N-oxidation of sparteine in man: A new pharmacogenetic defect

Eichelbaum, M. F., Spannbrucker, N., Steincke, B., & Dengler, H. J. (1979) · European Journal of Clinical Pharmacology · doi:10.1007/bf00562059 · Cited by 632

Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites

Butler, M. A., Lang, N. P., Young, J. F., Caporaso, N. E., Vineis, P., Hayes, R. B., Teitel, C. H., Massengill, J., Lawsen, M. F., & Kadlubar, F. F. (1992) · Pharmacogenetics · doi:10.1097/00008571-199206000-00003 · Cited by 419

Fluvoxamine is a potent inhibitor of cytochrome P4501A2

Brøsen, K., Skjelbo, E., Rasmussen, B. B., Poulsen, H. E., & Loft, S. H. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90272-x · Cited by 374

Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man

K�pfer, A., & Preisig, R. (1984) · European Journal of Clinical Pharmacology · doi:10.1007/bf00541938 · Cited by 363

Caffeine intake and small‐for‐gestational‐age birth: modifying effects of xenobiotic‐metabolising genes and smoking

Infante‐Rivard, C. (2007) · Paediatric and Perinatal Epidemiology · doi:10.1111/j.1365-3016.2007.00825.x · Cited by 28

Measurement of Duloxetine in Blood Using High-performance Liquid Chromatography with Spectrophotometric Detection and Column Switching

Waldschmitt, C., Vogel, F., Maurer, C., & Hiemke, C. (2007) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e31815d0dfa · Cited by 27

Population pharmacokinetics of caffeine in healthy male adults using mixed-effects models

Seng, K. Y., Fun, C. Y. D., Law, L. Y. L., Lim, W., Fan, W. P., & Lim, C. L. (2008) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2008.00976.x · Cited by 26

Expression of two drug‐metabolizing cytochrome P450‐enzymes in human salivary glands

Kragelund, C., Hansen, C., Torpet, L., Nauntofte, B., Brøsen, K., Pedersen, A., von Buchwald, C., Therkildsen, M. H., & Reibel, J. (2008) · Oral Diseases · doi:10.1111/j.1601-0825.2007.01415.x · Cited by 25

Consumption of Charcoal‐Broiled Meat as an Experimental Tool for Discerning CYP1A2‐Mediated Drug Metabolism in vivo

Larsen, J. T., & Brøsen, K. (2005) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2005.pto_97365.x · Cited by 25

The effects of caffeinated products on sleep and functioning in the military population: A focused review

Chaudhary, N. S., Taylor, B. V., Grandner, M. A., Troxel, W., & Chakravorty, S. (2021) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2021.173206 · Cited by 29

Functional characterization of eight human CYP1A2 variants

Palma, B. B., Sousa, M. S. E., Urban, P., Rueff, J., & Kranendonk, M. (2012) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32835c2ddf · Cited by 25

Low CYP1A2 activity associated with testicular cancer

Vistisen, K. K. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh102 · Cited by 24

Association between Common CYP 1 A 2Polymorphisms and Theophylline Metabolism in Non‐smoking Healthy Volunteers

Wang, L., Hu, Z., Deng, X., Wang, Y., Zhang, Z., & Cheng, Z. (2012) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12038 · Cited by 23

Individualization of Treatments with Drugs Metabolized by CES1: Combining Genetics and Metabolomics

Rasmussen, H. B., Bjerre, D., Línnet, K., Jűrgens, G., Dalhoff, K., Stefánsson, H., Hankemeier, T., Kaddurah-Daouk, R. F., Taboureau, O., Brunak, S., et al. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.7 · Cited by 23

Activation of aflatoxin B1 by expression of human CYP1A2 polymorphisms in Saccharomyces cerevisiae

Fasullo, M., Smith, A., Egner, P. A., & Cera, C. (2014) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2014.01.009 · Cited by 23

Pharmacology of Caffeine

Burdan, F. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-409517-5.00090-5 · Cited by 24

Sex-dependent modulation of treatment response

Rubinow, D. R., & Moore, M. (2004) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2004.6.1/drubinow · Cited by 23

Caffeine Increases Tear Volume Depending on Polymorphisms within the Adenosine A2a Receptor Gene and Cytochrome P450 1A2

Arita, R., Yanagi, Y., Honda, N., Maeda, S., Maeda, K., Kuchiba, A., Yamaguchi, T., Yanagihara, Y., Suzuki, H., & Amano, S. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2011.11.033 · Cited by 22

Moving towards Specific Nutrigenetic Recommendation Algorithms: Caffeine, Genetic Variation and Cardiovascular Risk

Caterina, R. D., & El‐Sohemy, A. (2016) · Lifestyle Genomics · doi:10.1159/000446801 · Cited by 22

How does caffeine influence memory? Drug, experimental, and demographic factors

Zhang, R.-C., & Madan, C. R. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.09.033 · Cited by 23

Cytochrome P4501A2 phenotype and bladder cancer risk: The Shanghai bladder cancer study

Li, T., Xiang, Y., Chan, K. K., Wang, R., Gao, Y., Yu, M. C., & Yuan, J. (2011) · International Journal of Cancer · doi:10.1002/ijc.26121 · Cited by 21

Pharmacogenetics of Antipsychotic Treatment in Schizophrenia

Pouget, J. G., & Müller, D. J. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-0956-8_14 · Cited by 21

Assessment of the Drug–Drug Interaction Potential Between Theacrine and Caffeine in Humans

He, H., Ma, D., Crone, L. B., Butawan, M. B., Meibohm, B., Bloomer, R. J., & Yates, C. R. (2017) · Journal of Caffeine Research · doi:10.1089/jcr.2017.0006 · Cited by 21

The Relationship Between Caffeine Intake and Dry Eye Disease

Magnø, M. S., Utheim, T. P., Morthen, M. K., Snieder, H., Jansonius, N. M., Hammond, C. J., & Vehof, J. (2022) · Cornea · doi:10.1097/ico.0000000000002979 · Cited by 20

Effect of Smoking on the Pharmacokinetics of Inhaled Loxapine

Takahashi, L. H., Huie, K., Spyker, D. A., Fishman, R. S., & Cassella, J. V. (2014) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000048 · Cited by 20

A twin study of the trough plasma steady-state concentration of metformin

Stage, T. B., Damkier, P., Pedersen, R. S., Christensen, M. M. H., Christiansen, L., Christensen, K., & Brøsen, K. (2015) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000133 · Cited by 20

The effects of caffeine supplementation on blood pressure in adults: A systematic review and dose-response meta-analysis

Abbas-Hashemi, S. A., Hosseininasab, D., Rastgoo, S., Shiraseb, F., & Asbaghi, O. (2023) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2023.09.923 · Cited by 19

Association between hypertension and coffee drinking based on CYP1A2 rs762551 single nucleotide polymorphism in Taiwanese

Hou, C.-C., Tantoh, D. M., Lin, C.-C., Chen, P.-H., Yang, H., & Liaw, Y. (2021) · Nutrition & Metabolism · doi:10.1186/s12986-021-00605-9 · Cited by 19

Cigarette Smoking and Clopidogrel Interaction

Swiger, K. J., Yousuf, O. K., Bliden, K. P., Tantry, U. S., & Gurbel, P. A. (2013) · Current Cardiology Reports · doi:10.1007/s11886-013-0361-7 · Cited by 19

Classical Twin Design in Modern Pharmacogenomics Studies

Rahmioğlu, N., & Ahmadi, K. R. (2010) · Pharmacogenomics · doi:10.2217/pgs.09.171 · Cited by 19

Hormonal Regulation of Hepatic Drug Biotransformation and Transport Systems

Ruiz, M. L., Mottino, A. D., Catania, V. A., & Vore, M. E. (2013) · Comprehensive physiology · doi:10.1002/cphy.c130018 · Cited by 20

Coffee and cardiovascular disease

Dewland, T. A., van Dam, R. M., & Marcus, G. M. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf421 · Cited by 18

The effect of ethinylestradiol‐containing contraceptives on the serum concentration of olanzapine and N‐desmethyl olanzapine

Haslemo, T., Refsum, H., & Molden, E. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03880.x · Cited by 18

CYP1A2 rs762551 polymorphism and risk for amyotrophic lateral sclerosis

Siokas, V., Karampinis, E., Aloizou, A., Mentis, A. A., Liakos, P., Papadimitriou, D. A., Liampas, I., Nasios, G., Bogdanos, D. P., Hadjigeorgiou, G. M., et al. (2020) · Neurological Sciences · doi:10.1007/s10072-020-04535-x · Cited by 17

Genetic Influences on the Pharmacokinetics of Orally and Intravenously Administered Digoxin as Exhibited by Monozygotic Twins

Birkenfeld, A. L., Jordan, J., Hofmann, U., Busjahn, A., Franke, G., Krüger, N., Igel, S., Mürdter, T. E., Drescher, S., Shi, S., et al. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.170 · Cited by 16

Coffee consumption has no effect on circulating markers of liver function but increases adiponectin concentrations: a systematic review and meta-analysis of randomized controlled trials

Linden-Torres, E., Zambrano-Galván, G., Sahebkar, A., Ríos-Mier, M., & Simental-Mendía, L. E. (2022) · Nutrition Research · doi:10.1016/j.nutres.2022.07.010 · Cited by 15

Clinical and Experimental Human Sleep-Wake Pharmacogenetics

Landolt, H., Holst, S. C., & Valomon, A. (2018) · Handbook of experimental pharmacology · doi:10.1007/164_2018_175 · Cited by 15

Pharmacogenetics of CYP1A2, Novel Polymorphisms and Haplotypes in Three Distinct Asian Populations

Lim, J. S. L., Singh, O., Ramasamy, R. D., Ramasamy, S., Subramanian, K., Lee, E. J. D., & Chowbay, B. (2010) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-10-sc-051 · Cited by 15

Pharmacogenomics and migraine: possible implications

Tfelt‐Hansen, P. C., & Brøsen, K. (2008) · The Journal of Headache and Pain · doi:10.1007/s10194-008-0009-y · Cited by 15

CYP1A2 genotype and rheumatoid arthritis in Koreans

Cornelis, M. C., Bae, S., Kim, I., & El‐Sohemy, A. (2009) · Rheumatology International · doi:10.1007/s00296-009-1050-0 · Cited by 14

Pharmacokinetic considerations concerning the use of bronchodilators in the treatment of chronic obstructive pulmonary disease

Matera, M. G., Rinaldi, B., Page, C. P., Rogliani, P., & Cazzola, M. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1530215 · Cited by 14

Pharmacogenetics of drug oxidation via cytochrome P450 (CYP) in the populations of Denmark, Faroe Islands and Greenland

Brøsen, K. (2015) · Drug Metabolism and Personalized Therapy · doi:10.1515/dmdi-2014-0029 · Cited by 13

The Reduction of the Combined Effects of Aflatoxin and Ochratoxin A in Piglet Livers and Kidneys by Dietary Antioxidants

Popescu, R. G., Avramescu, S. M., Marin, D. E., Țăranu, I., Georgescu, S. E., & Dinischiotu, A. (2021) · Toxins · doi:10.3390/toxins13090648 · Cited by 13

Pharmacogenetics of Antipsychotic Treatment in Schizophrenia

Elsheikh, S. S. M., Müller, D. J., & Pouget, J. G. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2573-6_14 · Cited by 13

A cytochrome P450 phenotyping cocktail causing unexpected adverse reactions in female volunteers

Pedersen, R. S., Damkier, P., Christensen, M. M. H., & Brøsen, K. (2013) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-013-1561-1 · Cited by 13

Genetic susceptibility in pharmacodynamic and pharmacokinetic pathways underlying drug-induced arrhythmia and sudden unexplained deaths

Martínez-Matilla, M., Blanco‐Verea, A., Santori, M., Ansede‐Bermejo, J. J., Ramos‐Luis, E., Gil, R., Bermejo, A. M., Lotufo-Neto, F., Hirata, M., Brisighelli, F., et al. (2019) · Forensic Science International Genetics · doi:10.1016/j.fsigen.2019.07.010 · Cited by 14

A double-blind, randomized, two-part, two-period crossover study to evaluate the pharmacokinetics of caffeine versus d9-caffeine in healthy subjects

Sherman, M. M., Tarantino, P. M., Morrison, D., Lin, C.-H., Parente, R. M., & Sippy, B. C. (2022) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2022.105194 · Cited by 12

Salivary caffeine metabolic ratio in alcohol-dependent subjects

Kukongviriyapan, V., Prawan, A., Gaysornsiri, D., Kukongviriyapan, U., Aiemsaard, J., & Senggunprai, L. (2004) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-004-0734-3 · Cited by 12

Hepatic CYP1A2 activity in liver tumors and the implications for preoperative volume-function analysis

Wuensch, T., Heucke, N., Wizenty, J., Quint, J., Sinn, B. V., Arsenić, R., Jara, M., Kaffarnik, M. F., Pratschke, J., & Stockmann, M. (2019) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00335.2018 · Cited by 12

Arousal and Behavior: Biopsychological Effects of Caffeine

Nehlig, A. (2004) · CRC Press eBooks · doi:10.1201/9780203618851-10 · Cited by 12

Caffeine intake during pregnancy

Olsen, J., & Bech, B. H. (2008) · BMJ · doi:10.1136/bmj.a2316 · Cited by 12

Coffee and Cardiovascular Health: A Review of Literature

Farraj, A., Akeredolu, T., Wijeyesekera, A., & Mills, C. E. (2024) · Nutrients · doi:10.3390/nu16244257 · Cited by 15

Health Status Is Affected, and Phase I/II Biotransformation Activity Altered in Young Women Using Oral Contraceptives Containing Drospirenone/Ethinyl Estradiol

Venter, G., der Berg, C. L. V., van der Westhuizen, F. H., & Erasmus, E. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph182010607 · Cited by 11

First metabolic profiling of 4-n-nonylphenol in human liver microsomes by integrated approaches to testing and assessment: Metabolites, pathways, and biological effects

Xie, R., Xu, Y., Ma, M., Wang, X., Zhang, L., & Wang, Z. (2023) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2023.130830 · Cited by 11

Systemic uptake of miconazole during vaginal suppository use and effect on CYP1A2 and CYP3A4 associated enzyme activities in women

Kjærstad, M. B., Nielsen, F., Noehr‐Jensen, L., Zwisler, S. T., Brøsen, K., & Andersen, H. R. (2010) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-010-0906-2 · Cited by 11

CYP1A2 IN A SMOKING AND A NON-SMOKING POPULATION: CORRELATION OF URINARY AND SALIVARY PHENOTYPIC RATIOS

Woolridge, H., Williams, J. H. P., Cronin, A. S., Nicola Evans, & Steventon, G. B. (2004) · Drug metabolism and drug interactions · doi:10.1515/dmdi.2004.20.4.247 · Cited by 11

Relationship between metabolic phenotypes and genotypes of CYP1A2 and CYP2A6 in the Nigerian population

Adehin, A., Bolaji, O. O., Maggo, S. D. S., & Kennedy, M. A. (2017) · Drug Metabolism and Personalized Therapy · doi:10.1515/dmpt-2016-0041 · Cited by 10

Caffeine levels and dietary intake in smokers with schizophrenia and bipolar disorder

Rosen, R., Ramasubramani, R. S., Benowitz, N. L., Gandhi, K. K., & Williams, J. M. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114989 · Cited by 10

Evaluation of the Effects of Therapeutic and Supratherapeutic Doses of Agomelatine on the QT/QTc Interval

Donazzolo, Y., Latreille, M., Caillaud, M.-A., Mocaër, E., & Seguin, L. (2014) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000136 · Cited by 10

Scientific Opinion on Flavouring Group Evaluation 49, Revision 1 (FGE.49Rev1): xanthine alkaloids from the priority list

Materials, E. E. P. O. F. C., Silano, V., Bolognesi, C., Castle, L., Cravedi, J., Engel, K., Fowler, P., Franz, R., Grob, K., Gürtler, R., et al. (2017) · EFSA Journal · doi:10.2903/j.efsa.2017.4729 · Cited by 10

Characterization of Clofazimine Metabolism in Human Liver Microsomal Incubation In Vitro

Saurav, H., Kim, M., Jony, M. R., Long, N. P., Cho, Y., Kim, D., & Shin, J. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00565-22 · Cited by 9

The impact of genetic variability on the relationship between caffeine and cardiometabolic outcomes: A systematic review

Virgili, J., Motitis, P., Julal, G., Mavrommatis, Y., & Pilić, L. (2023) · Nutrition Bulletin · doi:10.1111/nbu.12606 · Cited by 13

Altered activity of xenobiotic detoxifying enzymes at menopause – A cross-sectional study

Tsiokou, V., Kilindris, T. V., Begas, E., Kouvaras, E., Kouretas, D., & Asprodini, E. K. (2019) · Environmental Research · doi:10.1016/j.envres.2019.109074 · Cited by 9

Can the genotype or phenotype of two polymorphic drug metabolising cytochrome P450-enzymes identify oral lichenoid drug eruptions?

Kragelund, C., Hansen, C., Reibel, J., Nauntofte, B., Brøsen, K., Jensen, S. B., & Torpet, L. A. (2010) · Journal of Oral Pathology and Medicine · doi:10.1111/j.1600-0714.2010.00897.x · Cited by 9

Elucidation of the Mechanisms and Molecular Targets of Shuanglian Decoction for the Treatment of Hepatocellular Carcinoma Based on Network Pharmacology

He, K., Chen, H., Cao, T., & Lin, J. (2020) · ACS Omega · doi:10.1021/acsomega.0c05550 · Cited by 8

Biotechnology applications in precision food

Siddique, A., Tayyaba, T., Imran, M., & Rahman, A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90042-3.00013-x · Cited by 8

Does caffeine supplementation affect sleep in athletes? A systematic review of nine randomized controlled trials

Bodur, M., Barkell, J. F., Li, X., & Hezaveh, Z. S. (2024) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2024.11.007 · Cited by 15

Drug‐Drug Interaction Study to Assess the Effect of Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of the Novel Cereblon Modulator Avadomide (CC‐122) in Healthy Adult Subjects

Ogasawara, K., MacGorman, K., Liu, L., Chen, J., Carayannopoulos, L. N., Zhou, S. Y., Palmisano, M., & Li, Y. (2019) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1453 · Cited by 7

Arousal and Behavior

Smith, B., Osborne, A., Jones, H. A., White, T., & Mann, M. (2004) · Nutrition, brain, and behavior./Nutrition, brain and behavior · doi:10.1201/9780203618851.ch3 · Cited by 7

CYP 450 Enzymes in Drug Discovery and Development: An Overview

Xu, L. S., Das, B., & Prakash, C. (2012) · Encyclopedia of Drug Metabolism and Interactions · doi:10.1002/9780470921920.edm117 · Cited by 7

Measurement of Human Cytochrome P4501A2 (CYP1A2) Activity In Vitro

Polasek, T. M., Elliot, D. J., & Miners, J. O. (2006) · Current Protocols in Toxicology · doi:10.1002/0471140856.tx0419s27 · Cited by 6

Curative Effects of ZHENG-Based Fuzheng-Huayu Tablet on Hepatitis B Caused Cirrhosis Related to CYP1A2 Genetic Polymorphism

Li, Q., Guo, Z., Deng, X., Xu, L.-M., Gao, Y., Zhang, W., Wang, X., Xue, D., Lu, Y.-Y., Liu, P., et al. (2013) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2013/302131 · Cited by 6

CYP1A2 F21L and F186L Polymorphisms in an Italian Population Sample

Pucci, L., Geppetti, A., Maggini, V., Lucchesi, D., Rossi, A. M., & Longo, V. G. (2007) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.22.220 · Cited by 6

Population pharmacokinetics of theophylline in adult Chinese patients with asthma and chronic obstructive pulmonary disease

Ma, Y., Xue, L., Chen, X., Kang, Y., Wang, Y., & Wang, L. (2018) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-018-0636-6 · Cited by 5

Caffeine and Cardiovascular Disease: A Scientific Statement From the American Heart Association

Marcus, G. M., Hu, F. B., van Dam, R. M., Cornelis, M. C., Dewland, T. A., Kang, J., Larsson, S. C., Page, R. L., II, & Parekh, N. (2026) · Circulation · doi:10.1161/cir.0000000000001454 · Cited by 4

Similar adenosine neuromodulation in male and female hippocampal and prefrontocortical synapses of young and aged mice

Valladão, S. C., Lopes, C. R., Lopes, J. P., Piteira, M., Pandolfo, P., dos Santos‐Rodrigues, A., Agostinho, P. M., Tomé, Â. R., Cunha, R. A., & Ferreira, S. G. (2025) · Neuroscience Letters · doi:10.1016/j.neulet.2025.138306 · Cited by 4

Pharmacokinetics of Rasagiline in Healthy Adult Chinese Volunteers with Various Genotypes: A Single-Center, Open-Label, Multiple-Dose Study

Chen, X., Zhao, Q., Jiang, J., Liu, J., & Hu, P. (2016) · Clinical Drug Investigation · doi:10.1007/s40261-016-0380-4 · Cited by 4

Correlation between assessment of cytochrome P450 1A2 activity and enzyme activity scores, and their relation to clozapine exposure

Alarcan, H., Cannet, P., Camus, V., Fond, G. B., Zendjidjian, X. Y., Guilhaumou, R., & Quaranta, S. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15636 · Cited by 4

Polymorphisms in the gene encoding CYP1A2 influence prostate cancer risk and progression

VILČKOVÁ, M., Škereňová, M., Dobrota, D., Kaplán, P., Jurečeková, J., Kliment, J., Híveš, M., Dusenka, R., Evin, D., Brožová, M., et al. (2023) · Oncology Letters · doi:10.3892/ol.2023.13671 · Cited by 4

Clinically Significant Interactions with Antipsychotics

Lu, M., & Lane, H. (2016) · Springer eBooks · doi:10.1007/978-3-319-27883-4_16 · Cited by 4

Significance of the 13C-caffeine breath test for patients with cirrhosis.

Konstantinou, D., Margariti, E., Hadziyannis, E. S., Pectasides, D. G., & Papatheodoridis, G. (2014) · Europe PMC (PubMed Central) · Cited by 4

Priority topics for the development of risk assessment guidance by EFSA's Scientific Committee in 2016–2018

EFSA Scientific Committee (2016) · EFSA Journal · doi:10.2903/j.efsa.2016.4502 · Cited by 4

Influence of the CYP1A2 genotype on the exercise performance of physically active individuals under caffeine supplementation: a systematic review

Messenburger, G. P., Nuñez, F. F., Porepp, O. D. S. C., Collares, L. F., Delpino, F. M., Barros, C. C., & Pieniz, S. (2025) · Nutrition Research · doi:10.1016/j.nutres.2025.10.005 · Cited by 4

Sports Medicine Pearls and Pitfalls

Eichner, E. R. (2009) · Current Sports Medicine Reports · doi:10.1249/jsr.0b013e31819c79d0 · Cited by 3

Hormonal Regulation of Hepatic Drug Biotransformation and Transport Systems

Ruiz, M. L., Mottino, A. D., Catania, V. A., & Vore, M. E. (2013) · Comprehensive physiology · doi:10.1002/j.2040-4603.2013.tb00537.x · Cited by 3

Associations of CYP1A2 Polymorphisms with the Risk Haplotypes in Lung Cancer in the Slovak Population

Matáková, T., Halasova, E., Dzian, A., Hruby, R., Halaša, M., Javorka, K., & Škereňová, M. (2016) · Advances in experimental medicine and biology · doi:10.1007/5584_2016_220 · Cited by 3

Importance of pharmacogenetic and environmental factors for variation in caffeine disposition: with special emphasis on CYP1A2, CYP2A6, NAT2 and XO

Djordjević, N. (2012) · Figshare · Cited by 3

An Investigation into the Use of Dried Blood Spot Analysis in Pharmacokinetic Studies

Patel, P. (2011) · DMU Open Research Archive (De Montfort University) · Cited by 3

Four days of a moderate dose of caffeine does not alter raw bioelectrical impedance analysis parameters in healthy males

Francisco, R., Rosa, G. B., Júdice, P. B., Magalhães, J. P., Cruz, A. D., Sardinha, L. B., Lukaski, H. C., & Silva, A. M. (2025) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2025.08.005 · Cited by 3

Caffeine and clinical change in a patient with schizophrenia on a long-stay ward

Kim, A., & O'Hanlon, M. (2011) · Irish Journal of Psychological Medicine · doi:10.1017/s0790966700011988 · Cited by 2

Role of Caffeine in Sports Nutrition

Guimarães‐Ferreira, L., Trexler, E. T., Jaffe, D. A., & Cholewa, J. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-805413-0.00019-3 · Cited by 3

Whole Exome Sequencing Study Identifies Novel Rare Risk Variants for Habitual Coffee Consumption Involved in Olfactory Receptor and Hyperphagia

Cheng, B., Pan, C., Cheng, S., Meng, P., Liu, L., Wei, W., Yang, X., Jia, Y., Wen, Y. F., & Zhang, F. (2022) · Nutrients · doi:10.3390/nu14204330 · Cited by 2

Pharmacogenomics in Psychiatric Diseases

Kekić, A. (2023) · Springer eBooks · doi:10.1007/978-3-031-45903-0_9 · Cited by 3

Human genetics and caffeine: Functional single-nucleotide polymorphism and response to caffeine intake

Chmurzyńska, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13868-3.00053-3 · Cited by 2

Pharmacology of Caffeine

Torrisi, S. A., Rizzo, S., Godos, J., Grosso, G., & Leggio, G. M. (2025) · Royal Society of Chemistry eBooks · doi:10.1039/9781839166853-00388 · Cited by 2

Elucidate the origin of CYP flexible structural variation using molecular dynamics calculation

Ismael, M., & Carpio, C. A. D. (2011) · Journal of Toxicology and Environmental Health Sciences · doi:10.5897/jtehs.9000026 · Cited by 2

Genome-wide Association Study of Caffeine Consumption Using Coriell Personalized Medicine Collaborative Data

Kusic, D., Zajic, S. C., Gharani, N., Gordon, E. S., Schmidlen, T., Zhang, P., Gerry, N. P., & Scheinfeldt, L. (2023) · Genetics & Molecular Medicine · doi:10.33425/2689-1077.1020 · Cited by 2

Importance of Pharmacogenomics

Zanger, U. M., Klein, K., & Rieger, J. K. (2012) · Wiley eBooks · doi:10.1002/9783527630905.ch9 · Cited by 2

Cytochrome P450 Polymorphisms

Zanger, U. M. (2012) · Encyclopedia of Drug Metabolism and Interactions · doi:10.1002/9780470921920.edm009 · Cited by 2

Genetic Modifiers of Caffeine Consumption and Risk of Myocardial Infarction

Costa, L. A. D. (2011) · TSpace (University of Toronto) · Cited by 2

Genetic Modifiers of Caffeine and Endurance Performance in Athletes

Guest, N. S. (2019) · TSpace (University of Toronto) · Cited by 2

Caffeine intake and the plasma proteome

Tian, O., Josse, A. R., & El‐Sohemy, A. (2013) · The FASEB Journal · doi:10.1096/fasebj.27.1_supplement.1080.3 · Cited by 1

Heritability of Caffeine Metabolism: Environmental Effects Masking Genetic Effects on CYP1A2 Activity but Not on NAT2

Matthaei, J., Tzvetkov, M. V., Strube, J., Sehrt, D. B., Sachse-Seeboth, C., Hjelmborg, J., Möller, S., Halekoh, U., Hofmann, U., Schwab, M. G., et al. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.444 · Cited by 38

A twin study using unlabelled 12C and labeled 13C caffeine orally revealing common environmental effects on CYP1A2 activity but almost no heritability of CYP1A2 activity

Matthaei, J., Schwab, M., Kerb, R., Hofmann, U., Sehrt, D. B., Sachse-Seeboth, C., Strube, J., & Brockmöller, J. (2015) · German Medical Science (German Research Foundation) · doi:10.3205/15vklipha11

A population and family study of CYP1A2 using caffeine urinary metabolites

Catteau, A., Poisson, N., Bona�ti-Pelli�, C., Bechtel, Y. C., & Bechtel, P. R. (1995) · European Journal of Clinical Pharmacology · doi:10.1007/bf00196856 · Cited by 45

Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene.

Nakajima, M., Yokoi, T., Mizutani, M., Shin, S., Kadlubar, F. F., & Kamataki, T. (1994) · PubMed · Cited by 141

Importance of pharmacogenetic and environmental factors for variation in caffeine disposition: with special emphasis on CYP1A2, CYP2A6, NAT2 and XO

Djordjević, N. (2012) · Figshare · Cited by 3